An update on efficacy and safety comparison of biologics in treatment of inflammatory bowel disease targeting TNF-&#945;, interleukins, leukocyte trafficking, Janus-kinase, and sphingosine-1-phosphate receptor.

Sarangi, Sudhir Chandra; Pattnaik, Soumya S; Sinha, Surabhi; R, Govindaraj

An update on efficacy and safety comparison of biologics in treatment of inflammatory bowel disease targeting TNF-α, interleukins, leukocyte trafficking, Janus-kinase, and sphingosine-1-phosphate receptor.

Sarangi, Sudhir Chandra; Pattnaik, Soumya S; Sinha, Surabhi; R, Govindaraj.

Afiliación

Sarangi SC; Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India.
Pattnaik SS; Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India.
Sinha S; Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India.
R G; Department of Radiodiagnosis, NEIGRIHMS, Shilong, India.

Expert Rev Gastroenterol Hepatol ; 17(8): 837-861, 2023.

Article en En | MEDLINE | ID: mdl-36469630

Palabras clave

Adverse events; Crohn's disease; biologics; clinical response; randomized controlled trials; ulcerative colitis

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials / Risk_factors_studies / Systematic_reviews Idioma: En Revista: Expert Rev Gastroenterol Hepatol Asunto de la revista: GASTROENTEROLOGIA Año: 2023 Tipo del documento: Article País de afiliación: India

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google